Emerging drugs in endometriosis (Q36580603)

15 August 2017

1 reference

title

Emerging drugs in endometriosis (English)

1 reference

15 August 2017

1 reference

6

Thomas M D'Hooghe

1 reference

15 August 2017

4

Christel Meuleman

1 reference

15 August 2017

5

Jason M Mwenda

1 reference

15 August 2017

Attila Mihalyi

1

1 reference

15 August 2017

Peter Simsa

series ordinal

2

1 reference

15 August 2017

Kyama C Mutinda

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

503-524

1 reference

The genetic basis of endometriosis.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Revised American Society for Reproductive Medicine classification of endometriosis: 1996

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endometriosis and subfertility: is the relationship resolved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The impact of endometriosis upon quality of life: a qualitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Future directions in endometriosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Treatment of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endometriosis: treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

GnRH-antagonists in reproductive medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endometriosis: aetiology, pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Progestins for symptomatic endometriosis: a critical analysis of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Changes in quality of life after hormonal treatment of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Role of antiprogestational therapy for meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Progesterone antagonists and progesterone receptor modulators: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Noncontraceptive health benefits of combined oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Conventional medical therapies for endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Progestogens for endometriosis: forward to the past

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Invasiveness of endometriotic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Vascular development in endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Antiestrogens--tamoxifen, SERMs and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Aromatase in endometriosis and uterine leiomyomata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Treatment of severe postmenopausal endometriosis with an aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Anastrazole and oral contraceptives: a novel treatment for endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Use of GnRH antagonists in the treatment of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

High-dose pilot study with the novel progestogen dienogestin patients with endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Nonsteroidal progesterone receptor modulators: structure activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Cloning and sequence analysis of rabbit progesterone-receptor complementary DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Organisation of the entire rabbit progesterone receptor mRNA and of the promoter and 5' flanking region of the gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Progesterone receptor modulators and progesterone antagonists in women's health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Estrogen receptor null mice: what have we learned and where will they lead us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Immunolocalisation of oestrogen receptor beta in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Vascular endothelial growth factor (VEGF) in endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Antiangiogenic agents are effective inhibitors of endometriosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Antiangiogenesis therapy for endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endostatin inhibits the growth of endometriotic lesions but does not affect fertility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Angiogenesis and its control in the female reproductive system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Endometriosis is sustained by tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Tumour necrosis factor-alpha, interleukin-6 and interleukin-8 do not promote adhesion of human endometrial epithelial cells to mesothelial cells in a quantitative in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The PPARalpha-leukotriene B4 pathway to inflammation control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Thiazolidinedione inhibition of peritoneal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

IL-2, regulatory T cells, and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

The main function of IL-2 is to promote the development of T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

Proteomic approaches in endometriosis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

ESHRE guideline for the diagnosis and treatment of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.503

10.1517/14728214.11.3.503

21 January 2018

Identifiers

DOI

1 reference

release_lvckj3patvb5hacmx2kfqqfgfi

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lvckj3patvb5hacmx2kfqqfgfi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference